ExodusPoint Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

ExodusPoint Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,888	Closed	-$17.7M	–	1543
2025 Q4	$17.7M	Buy	82,888 +58,165	+235%	+$12M	0.14%	122
2025 Q3	$4.92M	Buy	24,723 +8,178	+49%	+$1.53M	0.05%	421
2025 Q2	$2.86M	Buy	+16,545	New	+$2.69M	0.03%	613
2023 Q4	–	Sell	-13,743	Closed	-$1.29M	–	1455
2023 Q3	$1.29M	Buy	+13,743	New	+$1.29M	0.01%	860
2021 Q3	–	Sell	-1,936	Closed	-$255K	–	2096
2021 Q2	$255K	Sell	1,936 -1,040	-35%	-$139K	﹤0.01%	1835
2021 Q1	$384K	Buy	2,976 +1,657	+126%	+$252K	0.01%	1521
2020 Q4	$220K	Buy	+1,319	New	+$218K	﹤0.01%	1683
2019 Q4	–	Sell	-13,482	Closed	-$1.3M	–	1514
2019 Q3	$1.3M	Sell	13,482 -16,009	-54%	-$1.79M	0.05%	330
2019 Q2	$3.4M	Sell	29,491 -13,463	-31%	-$1.61M	0.14%	101
2019 Q1	$5.06M	Buy	+42,954	New	+$3.76M	0.38%	48

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ExodusPoint Capital Management's ASND Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 82,888 shares — an estimated $17.7M sold.

ExodusPoint Capital Management first reported a position in ASND in Q1 2019 and held it in 10 quarters. The position peaked at $17.7M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

ExodusPoint Capital Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 82,888 Ascendis Pharma A/S shares in Q1 2026, an estimated $17.7M.
ExodusPoint Capital Management first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 10 quarters.
ExodusPoint Capital Management's Ascendis Pharma A/S position peaked at $17.7M in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.